ADC Linker

MC-VC-PAB-NH2 is a cleavable linker designed for the efficient synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. MC-VC-PAB-NH2 is ideal for researchers developing targeted cancer therapies, allowing for controlled drug delivery and reduced off-target effects.

Mal-PEG2-Val-Cit-PABA is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents within target cells, enhancing therapeutic efficacy while minimizing off-target effects. Its structure promotes stability during circulation and triggers cleavage in the presence of specific intracellular conditions, making it a valuable tool for ADC development and research applications in cancer treatment.

m-PEG10-alcohol is a non-cleavable linker comprised of a decaethylene glycol unit, primarily used in the design of antibody-drug conjugates (ADCs). This PEG-based compound serves as a versatile PROTAC linker, facilitating the development of proteolysis-targeting chimeras. Its structure enhances solubility and stability, making it suitable for various chemical biology applications, including targeted protein degradation studies.

NHPI-PEG4-C2-NHS ester is a versatile ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound serves as a critical bifunctional reagent, facilitating the stable attachment of therapeutic agents to antibodies. Its characteristics support the effective delivery of cytotoxic drugs, enhancing the specificity and efficacy of targeted cancer therapies. Research applications include the development and optimization of ADCs for improved therapeutic outcomes in oncology.

Fmoc-Gly3-Val-Cit-PAB is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the release of cytotoxic agents upon lysosomal cleavage, thereby enhancing the efficacy of targeted cancer therapies. It is utilized in the development of ADCs to improve specificity and reduce systemic toxicity in various oncological research applications.

Fmoc-Lys(DOTA)-OH is a versatile linker for antibody-drug conjugates (ADCs) that facilitates the conjugation of therapeutic agents to antibodies. Its DOTA moiety allows for stable coordination with various metal ions, enhancing the delivery of cytotoxic drugs to specific cells. This compound is instrumental in the development of targeted cancer therapies and other applications in drug delivery systems.

Fmoc-Val-D-Cit-PAB is a cleavable linker designed for antibody-drug conjugation (ADC) applications. This compound facilitates the selective release of cytotoxic agents in targeted therapies, enhancing the efficacy of treatments while minimizing off-target effects. Fmoc-Val-D-Cit-PAB is suitable for use in various research contexts, particularly in the development of novel ADCs for cancer therapy.

Mal-PEG4-Val-Cit-PAB-OH is a cleavable polyethylene glycol (PEG) linker designed for the synthesis of antibody-drug conjugates (ADCs). This linker features a Val-Cit dipeptide sequence that permits selective release of the cytotoxic drug upon cellular uptake. Its application enhances the therapeutic index of ADCs by improving solubility and stability while facilitating effective drug delivery in targeted cancer therapies.

Sulfo-LC-SPDP is a heterobifunctional crosslinker designed for antibody-drug conjugate (ADC) applications. It features a thiol-cleavable moiety that facilitates selective release of the drug component upon exposure to free thiol groups. Its membrane impermeability ensures that the linker remains within the cellular compartments, making it suitable for targeted delivery of therapeutics. This compound is widely utilized in research focusing on ADC development, enabling improved efficacy and specificity in cancer therapy.

(2R,4R)-4-Hydroxypyrrolidine-2-carboxylic acid hydrochloride functions as a non-cleavable linker in the development of antibody-drug conjugates (ADCs). Furthermore, it serves as an alkyl chain-based PROTAC linker, facilitating the synthesis of PROTACs. This compound plays a crucial role in advancing targeted protein degradation research, contributing to the exploration of innovative therapeutic strategies.

Mal-amido-(CH2COOH)2 is a maleimidoethyl-containing intermediate designed for use as a hydrophilic linker in antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies, enhancing the therapeutic efficacy while minimizing off-target effects. Its application in ADC development supports research aimed at precision medicine and targeted cancer therapies.

PEG4-SPDP is a cleavable linker specifically designed for use in antibody-drug conjugates (ADCs). It facilitates the stable attachment of cytotoxic agents to antibodies, allowing for targeted delivery and selective cytotoxicity. This reagent is essential for research applications in cancer therapeutics, enabling the development of innovative treatments through the precise modulation of targeted drug release in tumor environments.

Amino-Tri-(carboxyethoxymethyl)-methane hydrochloride is a cleavable PEG linker specifically designed for use in the synthesis of antibody-drug conjugates (ADCs). Its structural properties facilitate efficient conjugation, enhancing the therapeutic efficacy of ADCs. Additionally, this compound serves as a PEG-based PROTAC linker, enabling targeted protein degradation applications in research. Its versatile applications make it an essential reagent for advancing drug development and therapeutic strategies.

DBCO-NHS Ester 3 is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a dibenzocyclooctyne (DBCO) moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enabling efficient conjugation. DBCO-NHS Ester 3 is utilized in various applications involving targeted drug delivery and bioconjugation strategies in chemical biology and therapeutic development.

SCO-PEG3-NH2 is a cleavable antibody-drug conjugate (ADC) linker designed for effective drug delivery. This linker consists of three polyethylene glycol (PEG) units, facilitating enhanced solubility and stability. SCO-PEG3-NH2 serves as a copper-free click chemistry reagent, enabling catalyst-free conjugation in bioconjugation applications. It is suitable for research focused on the development of targeted therapeutics and bioconjugate systems.

Mal-PEG2-VCP-NB is a cleavable antibody-drug conjugate (ADC) linker featuring a Maleimide group, a polyethylene glycol (PEG) spacer of two units, and a valine-citrulline-p-nitrobenzyl (VCP-NB) moiety. This linker is designed to improve the delivery of cytotoxic agents specifically to target cells while minimizing off-target effects. Its application in ADC development supports research aimed at enhancing therapeutic efficacy in cancer treatment and advancing targeted drug delivery systems.

MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. Its specific cleavage mechanism allows for the release of the drug inside the target cells, making it a valuable tool for cancer research and therapeutic development in precision medicine.

Bis-SS-C3-NHS ester is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). It facilitates the covalent attachment of cytotoxic agents to antibodies, ensuring selective delivery to target cells. This linker is particularly valuable for enhancing the therapeutic efficacy of ADCs in cancer research and targeting specific tumor types, allowing for controlled release of active drugs upon internalization.

Cis-4-Hydroxy-L-proline hydrochloride is a cleavable ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound serves as a versatile tool in targeted drug delivery, enhancing the therapeutic efficacy of ADCs. Additionally, it functions as a PEG-based PROTAC linker, facilitating the development of proteolysis-targeting chimeras (PROTACs) for targeted protein degradation studies.

SCO-PEG2-NH2 is a cleavable ADC linker featuring two PEG units, designed to facilitate the delivery of cytotoxic agents in antibody-drug conjugates (ADCs). This linker serves as a copper-free click chemical reagent, enabling efficient catalyst-free click reactions. It is beneficial for researchers engaging in the development and optimization of ADCs, enhancing their therapeutic potential in targeted cancer treatment.

Gly-Gly-Gly-PEG4-methyltetrazine is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). It features a tetrazine moiety that facilitates rapid and selective conjugation through an inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) derivatives. This compound enhances the stability and efficacy of ADCs, making it valuable for targeted delivery of therapeutics in cancer research and other applications in bioconjugation.

Me-Tet-PEG8-Maleimide is an ADC linker featuring eight polyethylene glycol (PEG) units, designed for applications in antibody-drug conjugate (ADC) development. It incorporates a Tetrazine group capable of engaging in a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) compounds, facilitating targeted drug delivery. Additionally, the maleimide functionality exhibits stability in aqueous conditions, making it suitable for various bioconjugation studies and enhancing drug solubility and circulation time.

MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH is an antibody-drug conjugate (ADC) linker designed for effective drug-targeting applications. This compound forms a drug-linker conjugate with the cytotoxic agent Camptothecin, enhancing its delivery and selectivity. When conjugated to the antibody Trastuzumab, it facilitates the formation of highly specific ADCs, making it a valuable tool for targeted cancer therapy research.

Aminooxy-amido-PEG4-propargyl is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs). This versatile linker features an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in ADC synthesis enhances targeted delivery and efficacy of therapeutic agents, making it a valuable tool in cancer research and drug development.

Sulfo-SPP is a heterobifunctional crosslinker characterized by its thiol-cleavable nature and membrane impermeability. This reagent is designed for use in antibody-drug conjugate (ADC) applications, enabling the selective modification of biomolecules. Its unique properties facilitate the construction of stable conjugates while allowing for controlled release of therapeutic agents in target cells, making it a valuable tool in chemical biology and drug development research.

Fmoc-D-Val-Cit-PAB is a cleavable linker designed for antibody-drug conjugation (ADC). This compound facilitates the selective attachment of cytotoxic agents to antibodies, enhancing targeted delivery to diseased cells. Its unique cleavage properties enable the release of the active agent within the target tissue, making it a valuable tool in cancer therapeutics research and development.

Aminooxy-PEG2-BCN is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. This reagent features a BCN (cyclooctyne) moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its unique structure enables efficient conjugation in the development of targeted therapeutics, enhancing both delivery and efficacy of payloads in cancer research and other biomedical applications.

Mal-bis-PEG3-DBCO is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis, functioning through the efficient coupling of DBCO and azide moieties. This reagent incorporates a 3-unit polyethylene glycol (PEG) chain, enhancing solubility and biocompatibility. Its mechanism relies on strain-promoted alkyne-azide cycloaddition (SPAAC), making it ideal for precise conjugation applications in targeted drug delivery and cancer therapeutics research.

4-N3Pfp-NHS ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs), targeting the conjugation of therapeutic agents to antibodies. This compound features an azide group, enabling click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN groups. Its robust reactivity makes it an essential tool for enhancing the efficacy and selectivity of ADCs in cancer research and therapeutic development.

PC Alkyne-PEG4-NHS ester is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). Functioning as a PROTAC linker, this reagent features an alkyne group and participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions. Its unique structure enhances the specificity and efficiency of conjugating azide-containing molecules, making it valuable for various chemical biology applications, including targeted drug delivery and proteolysis targeting chimera (PROTAC) development.

Acid-PEG2-SS-PEG2-acid is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). This four-unit PEG-based linker facilitates the conjugation of drugs to antibodies, enhancing delivery while maintaining therapeutic efficacy. Its disulfide bond allows for selective cleavage in reducing environments, making it suitable for targeted drug release in various biological applications, including cancer therapies.

Fmoc-D-Val-D-Cit-PAB is a cleavable linker specifically designed for antibody-drug conjugation (ADC). This reagent facilitates the attachment of therapeutic agents to antibodies, enhancing targeted delivery to cancer cells. Its biocompatibility and stability make it ideal for research applications in the development of novel ADCs for improved cancer therapy.

Sulfo-SPP sodium is a heterobifunctional crosslinker that serves as an antibody-drug conjugate (ADC) linker. It features thiol-cleavable properties, enabling selective release of therapeutics in targeted cells. This membrane-impermeable linker is suitable for use in various applications, including the design and development of ADCs for targeted cancer therapies.

MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker designed for use in antibody-drug conjugates (ADCs). This linkage incorporates a maleimidocaproyl (Mc) group for efficient conjugation to antibodies, paired with a p-nitrophenol (PNP) moiety that facilitates attachment to antitumor agents. Its applications include enhancing targeted delivery of therapeutics and improving efficacy in cancer treatment research.

TCO-PEG4-DBCO is a versatile PROTAC linker known for its ability to facilitate the synthesis of proteolysis-targeting chimeras (PROTACs). This compound features a DBCO moiety that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing compounds, while the TCO component allows for inverse electron demand Diels-Alder (iEDDA) reactions with tetrazine derivatives. TCO-PEG4-DBCO finds applications in the development of antibody-drug conjugates (ADCs), enhancing the precision and efficacy of targeted therapeutics. Its unique chemical properties make it a valuable tool for researchers in chemical biology and drug development.

Propargyl-PEG8-bromide is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This non-cleavable linker includes an alkyne group, enabling its application in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its versatility makes it a valuable tool for researchers in the development of targeted therapeutics and for probing protein degradation mechanisms.

2,4-Diisopropylphenol is an important ADC linker that facilitates the conjugation of antibody-drug complexes. Its primary mechanism involves the formation of stable linkages between antibodies and cytotoxic agents, enhancing the therapeutic efficacy of targeted drug delivery systems. This compound is widely utilized in the development of antibody-drug conjugates (ADCs) for cancer therapeutics, allowing for precise targeting of tumor cells while minimizing off-target effects.

SPDV is a cleavable antibody-drug conjugate (ADC) linker designed to facilitate targeted delivery of therapeutics to cancer cells. Its primary mechanism involves selective cleavage in the presence of specific biological conditions, allowing for the release of cytotoxic agents directly within malignant tissues. SPDV is particularly useful in research applications focused on improving the efficacy of ADCs for the diagnosis and treatment of cancer and B cell proliferative diseases.

m-C-tri(CH2-PEG1-NHS ester) is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of antibodies to therapeutic agents, enhancing their delivery and efficacy while ensuring stability in circulation. Its application in ADC development supports targeted therapy research, particularly in cancer treatment and precision medicine.

m-PEG10-acid is a polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs) and PROTACs (Proteolysis Targeting Chimeras). This non-cleavable 10-unit PEG linker enhances solubility and stability, facilitating effective delivery of therapeutic agents to targeted cells. The compound is instrumental in chemical biology applications, aiding in the development of novel targeted therapies and research into protein degradation mechanisms.

N-Di(D-mannose)-PEG12-MC-VC-PAB-MMAE is an ADC linker designed for targeted cancer therapy. This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing selectivity and efficacy in tumor cells. Its utilization in antibody-drug conjugates provides a valuable tool for researchers investigating cancer treatments and mechanisms in various preclinical studies.

m-PEG5-succinimidyl carbonate is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs). This 5-unit polyethylene glycol (PEG) linker facilitates the covalent attachment of drugs to antibodies, enhancing the therapeutic efficacy of ADCs. Additionally, m-PEG5-succinimidyl carbonate serves as a versatile component in the synthesis of PROTACs (proteolysis-targeting chimeras), aiding in targeted protein degradation research applications.

N-Bromoacetyl-β-alanine is a versatile PROTAC linker that functions through targeted protein degradation pathways. This compound facilitates the synthesis of PROTACs, enabling the development of novel therapeutic strategies. Additionally, N-Bromoacetyl-β-alanine serves as a cleavable linker for antibody-drug conjugates (ADCs), enhancing the delivery of cytotoxic agents to specific cancer cells. Its utility in these applications makes it a valuable tool in chemical biology research.

Me-Tet-PEG4-Maleimide is an ADC linker featuring four PEG units that facilitates drug conjugation through its tetrazine group. It engages in inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctene (TCO) compounds, enabling precise targeting in drug delivery applications. The maleimide moiety offers controlled reactivity, making it suitable for studies requiring stability in biological systems while maintaining effective linker performance in therapeutic contexts.

AcBut is a cleavable linker specifically designed for antibody-drug conjugates (ADCs), facilitating the synthesis of Ozogamicin. This linker promotes stable attachment while enabling release of the active drug upon reaching the target site, thereby enhancing therapeutic efficacy. It is invaluable in the development of ADCs aimed at precision cancer therapies, where targeted cell killing is essential.

Mal-GGG-Bal-NHS ester is an ADC linker that facilitates the conjugation of cytotoxic agents to antibodies, enabling the targeted delivery of drugs to cancer cells. This compound is instrumental in the development of antibody-drug conjugates (ADCs) for therapeutic applications, enhancing the efficacy and selectivity of cancer treatments. Its reactive NHS ester group ensures efficient linkage to amine-containing biomolecules, making it a valuable tool in pharmaceutical research and drug development.

Mal-amido-PEG1-C2-NHS ester is a non-cleavable antibody-drug conjugate (ADC) linker that features a maleimide functionality and an NHS ester. This compound is designed for the efficient labeling of primary amines (-NH2) present in proteins, amine-modified oligonucleotides, and other amine-containing molecules. Its versatility in conjugation applications makes it suitable for targeted drug delivery and therapeutic development in bioconjugation research.

SPDH is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). It facilitates the selective release of therapeutic agents in targeted cancer therapies and B cell proliferative disorders. This compound enhances the efficacy of ADCs by ensuring the precise delivery of cytotoxic drugs to malignant cells, supporting advancements in targeted cancer treatment research.

Mal-PEG2-bis-PEG3-BCN is a cleavable linker designed for use in antibody-drug conjugates (ADCs). Featuring a BCN moiety, it facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enhancing conjugation efficiency. This reagent is ideal for the development of targeted therapies in cancer research and other applications requiring precise drug delivery mechanisms.

TCO-SS-amine is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). Featuring a TCO group, this reagent facilitates the inverse electron demand Diels-Alder reaction (iEDDA) with tetrazine-containing molecules. Its selective and efficient coupling capabilities make TCO-SS-amine a valuable tool in ADC development, enabling targeted delivery of therapeutic agents in cancer research and drug discovery applications.